| name | Silodosin (Rapaflo) |
| classification | Alpha-1A Adrenergic Antagonist |
| pharmacokinetics | | absorption | Rapidly absorbed after oral administration. Peak plasma concentrations are achieved within 2-4 hours. | | distribution | Distributed throughout the body. Highly bound to plasma proteins. | | metabolism | Primarily metabolized by the liver. Eliminated via the kidneys. | | elimination | Elimination half-life is approximately 8-10 hours. |
|
| suggested dosage | | adult male 25 years 70kg | Typically 8 mg once daily, taken with food. Adjustments may be necessary based on individual patient response and tolerance. | | important note | Dosage should be individualized based on the patient's condition and response. Consult a healthcare professional for specific dosage recommendations. |
|
| indications | Treatment of benign prostatic hyperplasia (BPH), specifically for reducing urinary symptoms like difficulty urinating, weak stream, and frequent urination. |
| safety in pregnancy | Category C. There is insufficient data on the use of Silodosin during pregnancy. It should be used only if the potential benefit justifies the potential risk to the fetus. Consult with a healthcare professional. |
| safety in breastfeeding | It is unknown whether Silodosin is excreted in breast milk. Due to the potential for adverse effects in the nursing infant, breastfeeding is not recommended while taking this medication. Consult a healthcare professional. |
| side effects | | 1 | Headache | | 2 | Dizziness | | 3 | Orthostatic hypotension (low blood pressure when standing up) | | 4 | Nasal congestion | | 5 | Nausea | | 6 | Diarrhea | | 7 | Ejaculatory dysfunction | | 8 | Abnormal ejaculation (retrograde ejaculation) | | 9 | Abnormal vision | | 10 | Elevated Liver Enzymes (Rare) | | 11 | Hypersensitivity Reactions (Rare) |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to Silodosin or any of its components. | | 2 | Severe hepatic impairment. | | 3 | Severe renal impairment (CrCl <30 mL/min) - use with caution and close monitoring if CrCl is 30-50 mL/min | | 4 | Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) - potential for increased Silodosin levels. | | 5 | Concurrent use with strong CYP3A4 inducers (e.g., rifampin) - potential for decreased Silodosin levels |
|
| interactions | | strong interactions | | 1 | | drug | Strong CYP3A4 inhibitors (ketoconazole, erythromycin) | | mechanism | Increased Silodosin levels, potentially leading to increased side effects |
| | 2 | | drug | Strong CYP3A4 inducers (rifampin) | | mechanism | Decreased Silodosin levels, potentially reducing effectiveness |
|
| | moderate interactions | | | other | Patients with pre-existing hypotension, or taking other medications that lower blood pressure should be monitored carefully |
|
| warnings and precautions | | 1 | Monitor blood pressure, particularly in patients with pre-existing hypertension or other cardiovascular conditions. | | 2 | Advise patients of the potential for dizziness or orthostatic hypotension, especially during the first few days of treatment. | | 3 | Use caution in patients with pre-existing renal or hepatic impairment. | | 4 | Monitor for and address any signs of abnormal ejaculation |
|
| additional informations | | 1 | Avoid driving or operating machinery until the response to the medication is known. | | 2 | Patients should be counseled about the potential for ejaculatory dysfunction. |
|
| important disclaimer | This information is for educational purposes only and does not constitute medical advice. Always consult with a healthcare professional for diagnosis and treatment. |
